Godavari Drugs Ltd
Godavari Drugs Ltd Live Price Chart
Godavari Drugs Ltd Technicals
| 20 Day | ₹ 85.910 |
| 50 Day | ₹ 85.589 |
| 100 Day | ₹ 84.975 |
| 200 Day | ₹ 87.139 |
| 20 Day | ₹ 87.170 |
| 50 Day | ₹ 85.752 |
| 100 Day | ₹ 83.006 |
| 200 Day | ₹ 86.217 |
Godavari Drugs Ltd Performance
| Previous Close | ₹ 79.09 |
| High | ₹ 80 |
| Volume | 4218 |
| 52W Range | ₹ 69.7 - ₹ 115 |
| Open | ₹ 79.09 |
| Low | ₹ 77.05 |
| Market Cap | ₹ 57 Cr |
Godavari Drugs Ltd Fundamentals
| ROCE | 11.106 |
| P/E Ratio | 13.590 |
| P/B Ratio | 1.370 |
| Industry P/E | 1.370 |
| Debt to Equity | 40.740 |
| ROE | 12.654 |
| EPS | 5.820 |
| Dividend Yield | 0.000 |
| Book Value | 57.561 |
| Face Value | 10.000 |
Godavari Drugs Ltd Financials
| Particulars | Y202503 | Y202403 | Y202303 | Y202203 | Y202103 |
|---|---|---|---|---|---|
| Total Revenue | 114.3273 | 157.3294 | 160.2801 | 161.3825 | 123.0803 |
| Total Expenses | 108.7019 | 150.3172 | 155.5749 | 154.3619 | 117.3739 |
| Profit After Tax | 4.38 | 5.5489 | 3.7858 | 5.2453 | 4.1281 |
Godavari Drugs Ltd Shareholding Pattern
| Promoter Holdings | 52.609 % |
| FIIs | 0.000 % |
| DIIs | 0.498 % |
| MutualFund | 0.000 % |
| Retail | 36.879 % |
| Others - | 10.014 % |
About Godavari Drugs Ltd
History of Godavari Drugs Ltd
Godavari Drugs Limited is engaged in the business of manufacture of Active Pharmaceutical Ingredients (API) and drug intermediates and fine chemicals catering to global life science industry. It works a manufacturing plant at Nanded, Maharashtra, India. Sulphamethoxazole (SMX), the main product of the company, is a widely used anti-bacterial drug enjoying good export demand. Company apart from its own products, explores continual opportunities for loan licence manufacturing with reputed multinational companies. The Company incorporated in December, 1987, has multiple production blocks for API's, drug intermediates and fine chemicals. The company has expanded its SMX capacity from 540 tpa to 720 tpa, integrating backward into the manufacture of drug intermediates, sulphamethoxide (cap.: 450 tpa) and diethyl oxalate, DEO (cap.: 750 tpa), and diversifying into the manufacture of trimetroprim, TMP (cap.: 144 tpa). The diversification into TMP is beneficial as SMX and TMP are used in combination to treat a wide variety of infections. The backward integration into SMO and DEO will enhance value-addition. In fact, Siris and Chemox Chemicals, both having good capacities of SMX, have recently gone in for the production of SMO. In 2000 the company introduced 'Pyrazyamide' in the market. Since the product is being well accepted in the market the company is planning to increase the capacity of 'Pyrazyamide' of 180 TPA and have also finalised on other products Cislactum,whi ...
